Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis
Avalyn Pharma presented new data at the ERS International Congress 2026 showing that in silico modeling predicts broad AP01 aerosol distribution throughout the lung, including in severely fibrotic lungs. The modeling used the Ebenbuild Twinhale platform with 3D lung models derived from HRCT scans of healthy, mild IPF, and severe IPF lungs, with alveolar and thoracic tissues accounting for the majority of deposited aerosol mass in all models — the primary sites of fibrotic remodeling.
Key figures
- Drug Name
- AP01 (inhaled pirfenidone)
- Phase Of Trial
- Phase 2b (MIST trial in progressive pulmonary fibrosis)
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.